NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $26.67 -0.53 (-1.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$26.43▼$26.6850-Day Range$24.57▼$30.2152-Week Range$16.88▼$31.99Volume409 shsAverage Volume3,329 shsMarket Capitalization$10.67 millionAssets Under Management$10.87 millionDividend Yield0.30%Net Expense Ratio0.79% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Virtus LifeSci Biotech Clinical Trials ETF alerts: Email Address About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC)The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.Read More BBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBC ETF News HeadlinesAugust 19, 2024 | benzinga.comFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | theglobeandmail.comTech ETFs on the Rise After Four Weeks in Deep RedSeptember 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.July 20, 2024 | lse.co.ukVirtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatMay 22, 2024 | bbc.comDrama at Trump trial as judge reprimands witness and clears courtSeptember 26, 2023 | bbc.co.ukSkipton hotel boss cleared as death crash trial collapsesJuly 30, 2023 | bbc.co.ukPuberty blockers to be given only in clinical researchSeptember 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.June 29, 2023 | ft.comBiotech begins human trials of drug designed by artificial intelligenceSee More Headlines Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings123 Fund Statistics Assets Under Management$10.87 million Average Daily Volume$1,572.40 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest3,500 shs Miscellaneous Outstanding Shares400,004Beta1.22 Creation Unit50,000 Creation Fee$500.00 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Ad Weiss RatingsAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.55%0.51%0.52%Other Expenses0.00%0.33%0.49%0.58%0.54%Total Expense0.79%0.71%0.71%0.74%0.71%Fee Waiver0.00%-0.45%-0.53%-0.68%-0.58%Net Expense0.79%0.61%0.61%0.58%0.59% Virtus LifeSci Biotech Clinical Trials ETF (BBC) Holdings & ExposureTop 10 BBC HoldingsBny Mellon Cash Reserve UsdHolding Weight: 1.96%Longboard Pharmaceuticals(NASDAQ:LBPH)Holding Weight: 1.44%Summit Therapeutics(NASDAQ:SMMT)Holding Weight: 1.34%AnaptysBio(NASDAQ:ANAB)Holding Weight: 1.29%Cassava Sciences(NASDAQ:SAVA)Holding Weight: 1.29%Nurix Therapeutics(NASDAQ:NRIX)Holding Weight: 1.19%Dyne Therapeutics(NASDAQ:DYN)Holding Weight: 1.14%Tango Therapeutics(NASDAQ:TNGX)Holding Weight: 1.14%Kymera Therapeutics(NASDAQ:KYMR)Holding Weight: 1.13%Perspective Therapeutics(NYSE:CATX)Holding Weight: 1.12%BBC Sector ExposureBBC Industry ExposureFull Holdings Details Similar ETFsJPMorgan Healthcare Leaders ETFNASDAQ:JDOCPrincipal Healthcare Innovators ETFNASDAQ:BTECHarbor Health Care ETFNYSEARCA:MEDIDirexion Daily Pharmaceutical & Medical Bull 3X SharesNYSEARCA:PILLHorizon Kinetics Medical ETFNASDAQ:MEDX BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $24.45 at the start of the year. Since then, BBC stock has increased by 9.1% and is now trading at $26.6655. View the best growth stocks for 2024 here. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Simon Property Group (SPG) and Cisco Systems (CSCO). This page (NYSEARCA:BBC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.